Health Care • Biotechnology: Pharmaceutical Preparations
$4.02 ▲ +0.03
(+0.75%)
MKT CAP: $260.1M • VOL: 777.1K
52W L $3 52W H $8
ROARABLE / RQD
D • 45/100
PIOTROSKI
3 / 9
IMRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$59.4M | -$64.1M | -$58.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$56.0M | -$61.0M | -$53.5M |
| EBITDA (Normalized) | -$59.3M | -$64.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$45.3M | -$55.0M | -$49.0M |
| Capital Expenditures (CapEx) | $142.2K | $84.9K | — |
| Free Cash Flow (FCF) | -$45.5M | -$55.1M | -$49.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $128.6M | $36.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $218.5M | $41.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMRX.